Repligen
RGEN
#2470
Rank
$7.44 B
Marketcap
$132.02
Share price
-1.15%
Change (1 day)
11.08%
Change (1 year)
Categories

Repligen (RGEN) - Total debt

Total debt on the balance sheet as of March 2026 : $0.68 Billion USD

According to Repligen 's latest financial reports the company's total debt is $0.68 Billion USD. A companyโ€™s total debt is the sum of all current and non-current debts.

Repligen - Total debt on balance sheet (from 2004 to 2026)

Total debt by year

Year Total debt Change
2025-12-31$0.68 B0.54%
2024-12-31$0.68 B-3.59%
2023-12-31$0.71 B68.29%
2022-12-31$0.42 B15.55%
2021-12-31$0.36 B32.91%
2020-12-31$0.27 B4.59%
2019-12-31$0.26 B154.44%
2018-12-31$0.10 B4.27%
2017-12-31$99.25 M4.18%
2016-12-31$95.27 M
2005-03-31$0.11 M40%
2004-03-31$0.08 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Pfizer
PFE
$63.73 B 9,168.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
$43.16 B 6,176.87%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
$20.27 B 2,848.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
$46.42 B 6,651.99%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
$25.42 M-96.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
$0.29 B-57.09%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
$0.40 B-40.93%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
$0.29 B-57.78%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
$1.43 B 109.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
$3.05 B 344.47%๐Ÿ‡บ๐Ÿ‡ธ USA